Carderock Capital Management Inc. Sells 2,905 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

• Carderock Capital Management cut its Intuitive Surgical stake by 16%, selling 2,905 shares and retaining 15,302 shares valued at approximately $6.22 million. Institutional investors collectively own 83.64% of ISRG.
• Intuitive Surgical reported a strong quarter, with revenue rising 21.7% year over year to $3.05 billion and earnings of $3.00 per share, beating estimates of $2.65. The company also cited continued international expansion and adoption of its robotic-surgery systems.
• Despite the earnings beat and a “Moderate Buy” analyst consensus, investors remain concerned about margin pressure from a roughly $450 million antitrust settlement, slowing U.S. da Vinci procedure growth and ISRG’s premium valuation of nearly 50 times earnings.

Carderock Capital Management Inc. reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 16.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,302 shares of the medical equipment provider's stock after selling 2,905 shares during the period. Carderock Capital Management Inc.'s holdings in Intuitive Surgical were worth $6,222,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ISRG. Bank of America Corp DE raised its stake in shares of Intuitive Surgical by 3.3% in the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider's stock worth $1,667,388,000 after buying an additional 116,292 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Intuitive Surgical during the second quarter valued at about $1,335,753,000. Amundi grew its stake in shares of Intuitive Surgical by 8.6% in the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider's stock worth $1,119,448,000 after purchasing an additional 193,096 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Intuitive Surgical by 95.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider's stock valued at $970,635,000 after buying an additional 1,027,475 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of Intuitive Surgical by 3.7% during the first quarter. Janus Henderson Group PLC now owns 1,643,060 shares of the medical equipment provider's stock worth $757,489,000 after purchasing an additional 58,587 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $452.29 on Friday. The company has a market capitalization of $156.78 billion, a price-to-earnings ratio of 49.76, a PEG ratio of 3.31 and a beta of 1.46. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88. The company's fifty day moving average price is $395.50 and its two-hundred day moving average price is $409.13.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts' consensus estimates of $2.65 by $0.35. The business had revenue of $3.05 billion for the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The firm's revenue was up 21.7% compared to the same quarter last year. During the same period last year, the business earned $2.40 EPS. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical reported third-quarter revenue of approximately $3.05 billion, up more than 20% year over year, while earnings exceeded consensus expectations. The company also highlighted continued international expansion and adoption of its robotic-surgery systems. Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story
• Positive Sentiment: Several firms remain constructive: BTIG, Stifel Nicolaus, Piper Sandler, and Oppenheimer reaffirmed or maintained Buy ratings. Baird also raised its price target, while Erste Group upgraded the stock to Buy. ISRG was added to the Zacks Rank #1 Strong Buy list. New Strong Buy Stocks for October 23rd
• Neutral Sentiment: The quarter included roughly $450 million of costs tied to an antitrust settlement, along with pricing-related pressure, which reduced margins. These items appear largely nonrecurring, but investors are assessing their effect on near-term profitability. Intuitive Surgical Reports Q3 2026 Earnings Impacted by $450M Antitrust Settlement
• Negative Sentiment: The key concern is that U.S. da Vinci procedure growth slowed to its lowest level since the COVID period. Investors worry that decelerating domestic demand could make it harder for Intuitive Surgical to sustain its premium valuation, which remains above 50 times earnings. Intuitive Surgical Sinks as U.S. da Vinci Growth Slows
• Negative Sentiment: RBC lowered its expectations for ISRG, and an analyst downgrade contributed to a gap lower in the shares. The market is emphasizing forward growth and valuation rather than the headline earnings beat. Intuitive Surgical Shares Gap Down Following Analyst Downgrade

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ISRG shares. Evercore set a $430.00 price target on Intuitive Surgical in a research report on Monday, July 6th. BTIG Research restated a "buy" rating and set a $454.00 price objective on shares of Intuitive Surgical in a report on Wednesday. Citigroup reduced their price objective on shares of Intuitive Surgical from $590.00 to $500.00 and set a "buy" rating for the company in a research note on Friday, July 17th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Finally, BNP Paribas Exane raised shares of Intuitive Surgical to an "outperform" rating in a research report on Tuesday, July 28th. Twenty-three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and a consensus target price of $493.54.

Insider Buying and Selling

In other news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total value of $151,600.00. Following the transaction, the executive vice president owned 5,320 shares of the company's stock, valued at $2,016,280. This trade represents a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Guthart sold 10,000 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the director owned 1,245,679 shares of the company's stock, valued at $498,271,600. The trade was a 0.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 12,370 shares of company stock valued at $4,891,989. 0.60% of the stock is owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.